Today I'm sitting down with Randy Teel, Ph.D., President and CEO of Arvinas, a clinical-stage biotech based in New Haven, Connecticut, that is doing something genuinely new in medicine.

Arvinas is pioneering a technology called PROTAC protein degradation. It's a platform that doesn't just block disease-causing proteins, but eliminates them entirely using the body's own disposal system to do it. It's a fundamental shift in how we think about drug design, and it's now reached a historic milestone: the first PROTAC ever to succeed in a Phase 3 clinical trial, with a regulatory filing now in front of the FDA.

• 01:19     Meet Randy Teel 
• 03:41     Stepping into the CEO role in February 2026 
• 13:17     What is a PROTAC and how it works 
• 17:37     Vepdegestrant and the first PROTAC approval 
• 23:43     Balancing partnerships versus keeping control of assets 
• 31:57     Key milestones to watch in the next 12–18 months

Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! 

Stay updated by subscribing to our newsletter

To dive deeper into the topic: 

• From undruggable to oral therapy: The rise of STAT6 degraders
• Big Pharma Strikes Megadeals In Targeted Protein Degradation
• This Biotech Destroys Cancer Proteins by Introducing Them to ‘Executioner’ Proteins